Another week, another round of developments across psychedelic medicine. Below is our recap of what mattered to investors for the week of January 5–11, 2026.
GH Research PLC (GHRS): FDA lifts clinical hold on GH001, clearing path for global Phase 3 in 2026
GH Research announced the FDA lifted the clinical hold on its Investigational New Drug application for GH001, its inhaled 5-MeO-DMT candidate for treatment-resistant depression, allowing U.S. patient enrollment to proceed. The resolution — following months addressing IND hold topics with no findings of respiratory toxicity — clears the way for a planned global pivotal Phase 3 program in 2026. GH Research held roughly $294 million in cash as of September 30, 2025, and its Phase 2b trial had shown a 73% six-month remission rate.
Source: globenewswire.com
Helus Pharma (formerly Cybin Inc.) (HELP): Helus Pharma begins trading on Nasdaq following Cybin rebrand
The company formerly known as Cybin commenced trading on the Nasdaq Global Market under the ticker HELP, doing business as Helus Pharma after its shares stopped trading on NYSE American on January 2. The uplisting completes the transition announced in December and positions the clinical-stage developer of CYB003 (depression) and CYB004 (anxiety) alongside a larger biopharma peer group as it approaches multiple 2026 data readouts.
Source: businesswire.com
Compass Pathways plc (CMPS): FDA accepts Compass Pathways' IND for COMP360 psilocybin in PTSD
Compass Pathways said the FDA accepted its Investigational New Drug application for COMP360 psilocybin in PTSD, enabling initiation of a Phase 2b/3 study (COMP202) in patients with PTSD. Alongside the acceptance, management hosted a webinar with clinical and industry experts on its PTSD plans and commercial preparations for treatment-resistant depression, expanding the psilocybin franchise into a second major psychiatric indication as the company moves toward a rolling NDA submission in TRD.
Source: businesswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.